3. Insmed Incorporated (NASDAQ:INSM)
Stock Upside: 111.74%
Market Capitalization: $20.44 billion
Insmed Incorporated (NASDAQ) ranks third among the most promising healthcare stocks according to Wall Street analysts, and Insmed Incorporated (NASDAQ) enters the top three with a rare disease and lung-drug story that analysts believe could still be underappreciated. Trading at $95.80, with Insmed Incorporated (NASDAQ) down 2.69%, the company has a market capitalization of $20.44 billion and a stock upside of 111.74%. For investors searching for biotech stocks with high upside, rare disease stocks, pulmonary arterial hypertension stocks, respiratory disease stocks, and healthcare stocks according to Wall Street analysts, Insmed Incorporated (NASDAQ) stands out because its pipeline and commercial products are both tied to serious diseases with meaningful unmet needs.
Insmed Incorporated (NASDAQ) received a fresh bullish signal on June 10, when Cantor Fitzgerald reaffirmed its Overweight rating on Insmed Incorporated (NASDAQ) and raised its price target from $230 to $235. For Insmed Incorporated (NASDAQ), that higher target matters because it suggests Cantor Fitzgerald sees more value in the company than the market is currently pricing in. The firm pointed to an upcoming data release for Insmed Incorporated (NASDAQ)’s experimental lung drug TPIP as a potential catalyst that investors may be underestimating.
Insmed Incorporated (NASDAQ)’s TPIP stands for Treprostinil Palmitil Inhalation Powder, an inhaled therapy being developed for pulmonary arterial hypertension, or PAH. For Insmed Incorporated (NASDAQ), TPIP is important because PAH is a serious lung and heart-related disease that causes high blood pressure in the arteries of the lungs, placing strain on the heart and limiting a patient’s ability to function. Inhaled therapies can be especially interesting in respiratory and pulmonary diseases because they deliver treatment directly through the lungs, and Insmed Incorporated (NASDAQ) is trying to build a stronger case for TPIP as part of its long-term pipeline.
Cantor Fitzgerald noted that it has been roughly a year since Insmed Incorporated (NASDAQ) first presented Phase 2b clinical trial results for TPIP in PAH. The next major moment for Insmed Incorporated (NASDAQ) is a one-year open-label extension update expected in Q3 2026. In simple terms, an open-label extension is the part of a clinical study where all patients receive the actual drug and are monitored over a longer period. For Insmed Incorporated (NASDAQ), this kind of data can help show whether TPIP’s benefits are durable and whether the safety profile remains manageable over time.
Cantor Fitzgerald believes that if Insmed Incorporated (NASDAQ)’s next TPIP data release is robust, the market may shift some focus away from Brinsupri, Insmed Incorporated (NASDAQ)’s drug for non-cystic fibrosis bronchiectasis. That point is important because Brinsupri posted blowout revenue at the end of Q1 2026, which may have caused investors to concentrate too heavily on that product while overlooking TPIP. For Insmed Incorporated (NASDAQ), the analyst argument is that TPIP may be significantly undervalued because the market is currently giving more attention to near-term revenue performance than to the company’s broader pipeline potential.
Insmed Incorporated (NASDAQ) is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. Insmed Incorporated (NASDAQ)’s approved product ARIKAYCE, an inhaled antibiotic delivered through the Lamira Nebulizer System, already gives the company commercial experience in inhaled rare-disease therapy. With a $20.44 billion market capitalization, 67 hedge fund holders, and a 111.74% stock upside estimate, Insmed Incorporated (NASDAQ) is one of the most prominent healthcare stocks with major analyst upside. For investors looking for rare disease biotech stocks and respiratory disease stocks to watch, Insmed Incorporated (NASDAQ) offers both existing commercial relevance and a potentially powerful upcoming pipeline catalyst.
Click next to see the following stock...
